New T-Cell Therapies for Brain Metastasis, CD133 in the Driver's Seat

Sloan, Anthony R.; Thapliyal, Mihika; Lathia, Justin D.

doi:10.1158/1078-0432.CCR-23-3051

Article navigation

CCR Translations| February 01 2024

New T-Cell Therapies for Brain Metastasis, CD133 in the Driver's Seat

Anthony R. Sloan

0000-0001-7994-3316

;

Anthony R. Sloan #

1Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.

2Case Comprehensive Cancer Center, Cleveland, Ohio.

Search for other works by this author on:

This Site

PubMed

Google Scholar

Mihika Thapliyal

0000-0002-0755-0393

;

Mihika Thapliyal #

1Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.

3Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio.

Search for other works by this author on:

This Site

PubMed

Google Scholar

Justin D. Lathia

0000-0003-3168-7290

Justin D. Lathia *

1Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.

2Case Comprehensive Cancer Center, Cleveland, Ohio.

3Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio.

4Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland, Ohio.

*Corresponding Author: Justin D. Lathia, Cleveland Clinic, 9500 Euclid Avenue, NE3-10, Cleveland, OH 44195. E-mail: [email protected]

Search for other works by this author on:

This Site

PubMed

Google Scholar

Author & Article Information

#

A.R. Sloan and M. Thapliyal contributed equally to this article.

*Corresponding Author: Justin D. Lathia, Cleveland Clinic, 9500 Euclid Avenue, NE3-10, Cleveland, OH 44195. E-mail: [email protected]

Clin Cancer Res 2024;30:477–9

Received: October 23 2023

Revision Received: November 10 2023

Accepted: November 21 2023

Online ISSN: 1557-3265

Print ISSN: 1078-0432

Funding

Funding Group:

Award Group:
- Funder(s):
  Lerner Research Institute, Cleveland Clinic
- Principal Award Recipient(s):
  A.R.
  M.
  J.D.
  
  Sloan
  Thapliyal
  Lathia
Award Group:
- Funder(s):
  Case Comprehensive Cancer Center, Case Western Reserve University (Case CCC)
- Principal Award Recipient(s):
  A.R.
  M.
  J.D.
  
  Sloan
  Thapliyal
  Lathia
Award Group:
- Funder(s):
  National Institutes of Health (NIH)
- Award Id(s):
  P01 CA245705
- Principal Award Recipient(s):
  A.R.
  M.
  J.D.
  
  Sloan
  Thapliyal
  Lathia
Award Group:
- Funder(s):
  National Institutes of Health (NIH)
- Award Id(s):
  R35 NS127083
- Principal Award Recipient(s):
  A.R.
  M.
  J.D.
  
  Sloan
  Thapliyal
  Lathia
Award Group:
- Funder(s):
  National Institutes of Health (NIH)
- Award Id(s):
  T32 CA059366
- Principal Award Recipient(s):
  A.R.
  
  Sloan
Award Group:
- Funder(s):
  National Institutes of Health (NIH)
- Award Id(s):
  R01 AG084250
- Principal Award Recipient(s):
  A.R.
  M.
  J.D.
  
  Sloan
  Thapliyal
  Lathia

2023

American Association for Cancer Research

Clin Cancer Res (2024) 30 (3): 477–479.

https://doi.org/10.1158/1078-0432.CCR-23-3051

Summary

Chimeric antigen receptor (CAR)-T cell immunotherapy has revolutionized cancer therapy for some advanced cancers, but success is predicated on identifying the correct cell surface target. In a recent article, the authors leveraged the cancer stem cell surface antigen CD133 to develop a CAR-T therapy for brain metastasis.

2023

American Association for Cancer Research

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.

New T-Cell Therapies for Brain Metastasis, CD133 in the Driver's Seat

Summary

Citing articles via

Email alerts

AACR Journals

New T-Cell Therapies for Brain Metastasis, CD133 in the Driver's Seat Available to Purchase

Summary

Sign in

Client Account

Citing articles via

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

New T-Cell Therapies for Brain Metastasis, CD133 in the Driver's Seat